Table 1 Clinical characteristics of 154 patients with OSCC after definitive CCRT
| Factors |
Training cohort n (%) |
Validation cohort n (%) | p value |
|---|---|---|---|
| Age, years | 0.087b | ||
| Median (range) | 61 (37–76) | 58 (40–76) | |
| Sex | 0.841c | ||
| Male | 77 (77.8%) | 42 (76.4%) | |
| Female | 22 (22.2%) | 13 (23.6%) | |
| Tumour location | 0.325c | ||
| Cervical | 16 (16.2%) | 13 (23.6%) | |
| Upper | 54 (54.5%) | 31 (56.4%) | |
| Middle | 29 (29.3%) | 11 (20.0%) | |
| T stagea | 0.469c | ||
| T2 | 11 (11.1%) | 10 (18.2%) | |
| T3 | 46 (46.5%) | 24 (43.6%) | |
| T4 | 42 (42.4%) | 21 (38.2%) | |
| N stagea | 0.655c | ||
| N0 | 36 (36.4%) | 22 (40.0%) | |
| N1 | 63 (63.6%) | 33 (60.0%) | |
| M stagea | 0.668c | ||
| M0 | 87 (87.9%) | 47 (85.5%) | |
| M1 | 12 (12.1%) | 8 (14.5%) | |
| Clinical stagea | 0.909c | ||
| II stage | 29 (29.3%) | 16 (29.1%) | |
| III stage | 58 (58.6%) | 31 (56.4%) | |
| IV stage | 12 (12.1%) | 8 (14.5%) | |
| Chemotherapy regimen | 0.559c | ||
| RT with PF | 91 (91.9%) | 49 (89.1%) | |
| RT with other regimens | 8 (8.1%) | 6 (10.9%) | |
| Dose regimen | 0.102c | ||
| 2.2 Gy × 30 F | 55 (55.6%) | 23 (41.8%) | |
| 2.0 Gy × 32 F | 44 (44.4%) | 32 (58.2%) |